A Phase 2a, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain

The primary objective of this study, in subjects with Neuropathic Corneal Pain, is to evaluate the efficacy and safety of OK-101 0.05% and 0.1% as compared to placebo instilled 4 times/day in subjects with neuropathic corneal pain, as assessed by visual analogue scale (VAS).

Start Date15 Oct 2024

Sponsor / Collaborator

OKYO Pharma Ltd.

[+1]

NCT05759208

/ CompletedPhase 2

A Phase 2, Multi-center, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of OK-101 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

The objective of this study is to compare the safety and efficacy of OK-101 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Start Date28 Apr 2023

Sponsor / Collaborator

OKYO Pharma Ltd.

[+1]

100 Clinical Results associated with Urcosimod

100 Translational Medicine associated with Urcosimod

100 Patents (Medical) associated with Urcosimod

Literatures (Medical) associated with Urcosimod

Plants (Basel, Switzerland)Q3 · BIOLOGY

Use of Non-Destructive Measurements to Identify Cucurbit Species (Cucurbita maxima and Cucurbita moschata) Tolerant to Waterlogged Conditions

Q3 · BIOLOGY

ArticleOA

Author: Lin, Kuan-Hung ; Su, Yi-Ru ; Huang, Meng-Yuan ; Lin, Hsin-Hung

Limited information is available regarding the physiology of squash plants grown under waterlogging stress. The objectives of this study were to investigate the growth and physiological performances of three cucurbit species, Cucurbita maxima cultivar (cv.) OK-101 (OK) and Cucurbita moschata cv. Early Price (EP) and Strong Man (SM), in response to waterlogging conditions, and to develop a precise, integrated, and quantitative non-destructive measurement of squash genotypes under stress. All tested plants were grown in a growth chamber under optimal irrigation and growth conditions for a month, and the pot plants were then subjected to non-waterlogging (control) and waterlogging treatments for periods of 1, 3, 7, and 13 days (d), followed by a 3-d post-waterlogging recovery period after water drainage. Plants with phenotypes, such as fresh weight (FW), dry weight (DW), and dry matter (DM) of shoots and roots, and various physiological systems, including relative water content (RWC), soil and plant analysis development (SPAD) chlorophyll meter, ratio of variable/maximal fluorescence (Fv/Fm), quantum photosynthetic yield (YII), normalized difference vegetation index (NDVI), and photochemical reflectance index (PRI) values, responded differently to waterlogging stress in accordance with the duration of the stress period and subsequent recovery period. When plants were treated with stress for 13 d, all plants exhibited harmful effects to their leaves compared with the control, but EP squash grew better than SM and OK squashes and exhibited stronger tolerance to waterlogging and showed less injury. Changes in the fresh weight, dry weight, and dry matter of shoots and roots indicated that OK plants suffered more severely than EP plants at the 3-d drainage period. The values of RWC, SPAD, Fv/Fm, YII, NDVI, and PRI in both SM and OK plants remarkably decreased at waterlogging at the 13-d time point compared with controls under identical time periods. However, the increased levels of SPAD, Fv/Fm, YII, NDVI, and PRI observed on 7 d or 13 d of waterlogging afforded the EP plant leaf with improved waterlogged tolerance. Significant and positive correlations were observed among NDVI and PRI with SPAD, Fv/Fm, and YII, indicating that these photosynthetic indices can be useful for developing non-destructive estimations of chlorophyll content in squashes when screening for waterlogging-tolerant plants, for establishing development practices for their cultivation in fields, and for enhanced cultivation during waterlogging in frequently flooded areas.

Graefe's Archive for Clinical and Experimental Ophthalmology

Quintessence of currently approved and upcoming treatments for dry eye disease

Review

Author: Sawale, Gayatri ; Ghuge, Santosh ; Patil, Sunanda ; Sathaye, Sadhana

Dry eye disease (DED), also known as dry eye syndrome, is a multifactorial ocular surface disease. The aim of this review is to present the details of currently approved and upcoming treatment options for DED in a nutshell. We conducted a thorough literature search using PubMed and searched US FDA website, clinicaltrials.gov, and data available in public domain for currently approved and upcoming treatment options for DED. Currently, the US Food and Drug Administration (FDA)-approved medical treatments for treatment of DED include cyclosporine formulations (RESTASIS^® [cyclosporine 0.05% ophthalmic emulsion], VEVYE^® [cyclosporine 0.1% ophthalmic solution], and CEQUA™ [cyclosporine 0.09% ophthalmic solution]), XIIDRA^® (lifitegrast), a leukocyte function-associated antigen-1 (LFA-1)/intracellular adhesion molecule-1(ICAM-1) inhibitor, EYSUVIS™ (loteprednol etabonate ophthalmic suspension 0.25%), a corticosteroid, and MIEBO™ (perfluorohexyloctane ophthalmic solution), a semifluorinated alkane. TYRVAYA™ (varenicline solution nasal spray), a cholinergic agonist, is another formulation approved for the treatment of the signs and symptoms of DED. The medical devices approved for treating DED due to meibomian glands dysfunction (MGD) include Lumenis OptiLight™ (intense pulsed light [IPL] device), TearCare^® system, and TearScience™ LipiFlow™ thermal pulsation system. Punctal plugs are another treatment option approved for management of DED. There are hundreds of clinical studies evaluating newer treatments for managing the signs and symptoms. Cyclosporine formulations TJO-087 (cyclosporine A nanoemulsion 0.08%), SCAI-001 eye drops (cyclosporine 0.01%, 0.02%) are being evaluated against RESTASIS^® and other approved treatments. The potential treatments being assessed include IC 265, OK-101, PL9643, SYL1001 (tivanisiran), SHJ002, OXERVATE^® (cenegermin-bkbj ophthalmic solution 0.002%), HBM9036 (tanfanercept ophthalmic solution), OCS-02 (licaminlimab), MIM-D3 (tavilermide ophthalmic solution 5%), AR-15,512, BRM421, reproxalap, and AZR-MD-001 (selenium sulphide ointment 0.5%). The pathophysiology of DED is complex and multifactorial; there is a need to understand it even deeper. The new treatments and different delivery systems seem promising and provide a hope of effective treatment for DED.

100

News (Medical) associated with Urcosimod

12 Feb 2026

·www.biospace.com

OKYO Pharma Announces Public Offering of Ordinary Shares

LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering (the “Offering”). All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in this Offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the size or terms of the Offering. Piper Sandler & Co. is acting as the sole book-running manager for the Offering. The Company intends to use the net proceeds from the Offering primarily for clinical development of its product candidates, general corporate purposes and working capital. The securities are being offered and sold pursuant to a shelf registration statement on Form F-3 (File No. 333-293145), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2026, and declared effective on February 10, 2026. The Offering is being made only by means of a prospectus supplement and the accompanying base prospectus, as may be further supplemented by any free writing prospectus that the Company may the SEC. A preliminary prospectus supplement describing the terms of the proposed Offering has been filed with the SEC and is available on the SEC’s website at The final prospectus supplement relating to the Offering will be filed with the SEC and will also be available on the SEC’s website. Copies of the preliminary prospectus supplement, the final prospectus supplement (when available) and the accompanying base prospectus relating to the Offering can also be obtained from Piper Sandler & Co. at 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attn: Prospectus Department, or via email at prospectus@psc.com or telephone at (800) 747-3924. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year. Forward-Looking Statements Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the proposed terms of the proposed offering, completion, timing and size of the proposed offering and the expected use of proceeds from the offering. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this press release. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering, risks disclosed in the section titled “ Risk Factors ” included in the preliminary prospectus supplement filed with the SEC on February 12, 2026, and risks disclosed in other documents the Company files from time to time with the SEC. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. For further inquiries: OKYO Pharma Ltd Paul Spencer, Business Development, and Investor Relations +44 (0) 207 495 2379 Email: info@okyopharma.com

Phase 2

12 Feb 2026

·www.biospace.com

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the “Offering”) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to the Company from the Offering, before deducting offering expenses payable by the Company and discounts, will be approximately $20 million. Assuming full exercise by the underwriter of its option to purchase additional ordinary shares, the gross proceeds to the Company from the Offering would be approximately $23 million, before deducting offering expenses payable by the Company and discounts. The Company intends to use the net proceeds from the Offering primarily for clinical development of its product candidates, general corporate purposes and working capital. Piper Sandler & Co. is serving as the sole manager for the Offering. The Offering is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions. The securities are being offered and sold pursuant to a shelf registration statement on Form F-3 (File No. 333-293145), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2026, and declared effective on February 10, 2026. The Offering is being made only by means of a preliminary prospectus supplement and the accompanying base prospectus, as may be further supplemented by any free writing prospectus that the Company may the SEC. The final prospectus supplement relating to the Offering will be filed with the SEC and will also be available on the SEC’s website. Copies of the preliminary prospectus supplement, the final prospectus supplement (when available) and the accompanying base prospectus relating to the Offering can also be obtained from Piper Sandler & Co. at 350 North 5 th Street, Suite 1000, Minneapolis, MN 55401, Attn: Prospectus Department, or via email at prospectus@psc.com or telephone at (800) 747-3924. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year. Forward-Looking Statements Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the closing of the Offering and the expected use of proceeds from the Offering. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this press release. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the Offering, risks disclosed in the section titled “Risk Factors” included in the preliminary prospectus supplement filed with the SEC on February 12, 2026, and risks disclosed in other documents the Company files from time to time with the SEC. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. For further inquiries: OKYO Pharma Ltd Paul Spencer, Business Development, and Investor Relations +44 (0) 207 495 2379 Email: info@okyopharma.com

Phase 2

11 Feb 2026

·www.biospace.com

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, a leading healthcare-focused investment bank as the sales agent, replacing its previous ATM facility with B. Riley Securities Inc. This strategic move allows OKYO Pharma to continue accessing the capital markets efficiently through an ATM program, enabling the sale of common shares directly into the market from time to time, at prevailing market prices, subject to market conditions and the Company's discretion. "We are excited to partner with Leerink Partners to establish this new ATM facility," said Keeren Shah, Chief Financial Officer of OKYO Pharma. "Leerink's deep expertise in the biotech sector, proven track record in executing ATM programs, and strong relationships in the investor community make them an ideal partner as we advance our pipeline, including our lead candidate urcosimod for neuropathic corneal pain. This transition enhances our financial flexibility to support ongoing clinical development and corporate objectives without committing to a fixed equity raise." The ATM facility provides OKYO Pharma the ability to raise capital opportunistically while minimizing market disruption. Sales under the program, if any, will be made pursuant to a prospectus supplement and accompanying base prospectus filed with the U.S. Securities and Exchange Commission (SEC). Leerink Partners will act as the exclusive sales agent and receive a commission equal to 3.0% of gross proceeds from any shares sold. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year. For further information, please visit . Forward-Looking Statements Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2025. The company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements, except as may be required by law. For further inquiries: OKYO Pharma Ltd Paul Spencer, Business Development, and Investor Relations +44 (0) 207 495 2379 Email: info@okyopharma.com

Phase 2

100 Deals associated with Urcosimod

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Corneal Diseases	Phase 2	United States	OKYO Pharma Ltd.	15 Oct 2024
Neuralgia	Phase 2	United States	OKYO Pharma Ltd.	15 Oct 2024
Dry Eye Syndromes	Phase 2	United States	OKYO Pharma Ltd.	28 Apr 2023
Conjunctivitis, Allergic	Preclinical	United States	OKYO Pharma Ltd.	15 Jul 2022
Uveitis	Preclinical	United States	OKYO Pharma Ltd.	15 Jul 2022
Ocular inflammation	Preclinical	United Kingdom	OKYO Pharma Ltd.	23 Jan 2019
COVID-19	Discovery	United Kingdom	OKYO Pharma Ltd.	19 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


GlobeNewswire Manual	Phase 2	Corneal Diseases \| Neuralgia	18	Urcosimod 0.05%	vajcfgxqou(kkvbfylgqm) = mtspqagpmq wmplirpjqr (rjjpovffbh, 1.55 - 5.67) View more	Positive	11 Dec 2025
				Placebo	vajcfgxqou(kkvbfylgqm) = wtaydczenv wmplirpjqr (rjjpovffbh, -3.76 to 0.63) View more
NCT06637527 (PipelineReview) Manual	Phase 2	Pain	18	Urcosimod 0.05%Urcosimod 0.05%	lczcgtlrvn(ywpdsgeopz) = fatcqlraff zgtziqwmiy (tvjhwpzdoo ) View more	Positive	16 Jul 2025
				Placebo	lczcgtlrvn(ywpdsgeopz) = djkelwintt zgtziqwmiy (tvjhwpzdoo ) View more
NCT05759208 (GlobeNewswire) Manual	Phase 2	Dry Eye Syndromes	240	OK-101OK-101 ophthalmic solution	evauhbtkae(izajypzrsb) = fmugpauyiy herhdvppgf (dsmzdxcung ) Met View more	Positive	10 Jul 2024
				Placebo	evauhbtkae(izajypzrsb) = nnslmepzjd herhdvppgf (dsmzdxcung ) Met View more
NCT05759208 (Corporate Publications) Manual	Phase 2	Dry Eye Syndromes	240	OK-101 0.05%	-	Positive	22 Mar 2024
				OK-101 0.1%
NCT05759208 (PipelineReview) Manual	Phase 2	Dry Eye Syndromes	240	OK-101	yikfmzydyq(umyhabhrvc): P-Value = 0.034 View more	Positive	08 Jan 2024
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Urcosimod

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation